Table 2.
Baseline characteristics of patients
| Characteristic | Group A (n = 19) | Group B (n = 23) | P |
|---|---|---|---|
| Age (years; mean ± SD) | 57 ± 11 | 60 ± 9 | NS |
| Men/women | 8/11 | 8/15 | NS |
| Postdialysis body weight (kg; mean ± SD) | 57.7 ± 8.5 | 55.7 ± 13.8 | NS |
| BMI (mean ± SD) | 23.3 ± 3.4 | 23.2 ± 3.9 | NS |
| Diabetes (n [%]) | 2 (10.5) | 5 (21.7) | NS |
| IHD/CVA/PVD (n [%]) | 7 (36.8) | 3 (13.0) | NS |
| Causes of ESRD (n [%]) | |||
| glomerulonephritis | 6 (31.6) | 7 (30.4) | |
| unknown | 8 (42.1) | 7 (30.4) | |
| lupus nephritis | 1 (5.3) | 3 (13.0) | |
| hypertensive nephropathy | 1 (5.3) | 2 (8.7) | |
| diabetic nephropathy | 0 (0.0) | 2 (8.7) | |
| other | 3 (15.8) | 2 (8.7) | |
| HD, sessions/week (thrice/twice per week) | 12/7 | 16/7 | NS |
| History of transplantation (n [%]) | 4 (21.1) | 2 (8.7) | NS |
| Years on PD (before HD; mean ± SD) | 3.4 ± 3.1 | 3.1 ± 2.9 | NS |
| Years on HD (mean ± SD) | 4.2 ± 3.7 | 5.1 ± 3.1 | NS |
| Total years on dialysis (PD + HD; mean ± SD) | 7.6 ± 3.6 | 8.2 ± 2.8 | NS |
| ACEI/ARA (n [%]) | 7 (36.8) | 7 (30.4) | NS |
| HMG-CoA reductase inhibitor (n [%]) | 4 (21.1) | 2 (8.7) | NS |
| EPO (n [%]) | 11 (57.9) | 18 (78.3) | NS |
BMI, body mass index; CVA, cerebrovascular accident; EPO, erythropoietin; IHD, ischemic heart disease; PD, peritoneal dialysis; PVD, peripheral vascular disease.